BIOBIJOU Co., Ltd.
KOSDAQ-listed aesthetics exporter behind HA skin booster CANDOLOV SERUM and filler brands COLENA and CANDORLOV.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2018 and listed on KOSDAQ in 2025, BIOBIJOU is a hyaluronic acid (HA)-based skin booster and filler company focused on aesthetics exports. Its products include the cross-linked HA skin booster CANDOLOV SERUM, the non-cross-linked ASCENART AQUA, and filler brands COLENA PREMIUM and CANDORLOV, alongside OEM products including the COLENA CE filler, the botulinum-toxin-based ELLEROX, and the CDL Cosmetics skincare brand. Its filler products use a patented dialysis device (registration no. 10-2662592) to resolve BDDE residue issues, its CANDOLOV SERUM applies a patented cross-linked HA composition (registration no. 10-2686600), it holds exclusive distribution rights for the exosome product ASCE+ in China, and CDL Cosmetics has entered the North American market via a D2C model.
Products & technology
- CANDOLOV SERUMCross-linked HA skin booster
- ASCENART AQUANon-cross-linked HA skin booster
- SPEETIQUELSkin booster with Acetyl Hexapeptide-8
- COLENA PREMIUMHA dermal filler
- CANDORLOVHA dermal filler
- COLENA CEDermal filler (OEM)
- ELLEROXBotulinum toxin A wrinkle treatment (OEM)
- CDL CosmeticsSkincare (cream, serum, mist, mask pack)
- ASCE+Exosome product
Regulatory approvals
data.go.kr10 Korean MFDS device approvals · 2021–2026
- MFDSGraft/prosthesis, biomaterial2026-04-02Product approval · Class 4제허 26-253 호
- MFDSGraft/prosthesis, biomaterial2025-11-07Product approval · Class 4제허 25-750 호
- MFDSGraft/prosthesis, biomaterial2025-10-21Product approval · Class 4제허 25-708 호
- MFDSGraft/prosthesis, biomaterial2025-09-11Product approval · Class 4제허 25-633 호
- MFDSGraft/prosthesis, biomaterial2025-09-11Product approval · Class 4제허 25-631 호
- MFDSGraft/prosthesis, biomaterial2025-02-25Product approval · Class 4제허 25-111 호
- MFDSGraft/prosthesis, biomaterial2024-08-05Product approval · Class 4제허 24-525 호
- MFDSGraft/prosthesis, biomaterialRevoked2024-05-14Product approval · Class 4제허 24-328 호
- MFDSGraft/prosthesis, biomaterial2022-07-11Product approval · Class 4제허 22-441 호
- MFDSGraft/prosthesis, biomaterial2021-03-15Product approval · Class 4제허 21-190 호
R&D and key agreements
Source: DART corporate disclosure가교 히알루론산 조성물 기술 · 특허 등록 10-2686600 · Applied to CANDOLOV SERUM
가교제 투석 제거장치 기술 · 특허 등록 10-2662592 · Resolves BDDE residue issue in fillers
LNP(지질나노입자) 기술 적용 아세나르트 라인업 확장
Companies approved for the same productsBiotech & Drug Discovery
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
Founded in 2003 and KOSDAQ-listed in 2021, BioPlus develops HA-based bio medical devices and biopharmaceuticals using its proprietary MDM Technology platform.
Founded and listed on the KOSDAQ in 2016, BNC Korea is a biohealthcare company specializing in HA fillers, botulinum toxin, and dermo-cosmetics.
KOSDAQ-listed aesthetics and CMO company behind the Elravie/Revolax hyaluronic-acid fillers and Leedstox botulinum toxin.
KOSDAQ-listed medical device maker producing disposable acupuncture needles, cupping cups, and hyaluronic acid dermal fillers.
Founded 2009, listed on KOSDAQ in 2019, JETEMA develops hyaluronic acid fillers, botulinum toxin biopharmaceuticals, and lifting threads.
KOSDAQ-listed medical device company producing PDRN pharmaceuticals, HA fillers, and Rejuran-branded cosmetics.
KOSDAQ-listed comprehensive healthcare and pharmaceutical company behind the gum treatment Insadol and the wound-care ointment Madecassol.
CAREGEN develops peptide-based cosmeceuticals sold in 130 countries and ophthalmic drug candidates CG-P5 and CG-T1.
KOSDAQ-listed pharmaceutical company behind the world's first oral paclitaxel Liporaxel (DHP107) and the Amalian dermal filler.
L&C BIO manufactures human tissue grafts across 11 tissue types, including the acellular dermal matrix MegaDerm, plus tissue-based medical devices.
Founded in 2013 and KOSDAQ-listed in 2018, T&R Biofab commercializes 3D bioprinting systems, bioinks, and biodegradable scaffolds.
KOSDAQ-listed pharmaceutical company producing a diverse, low-volume portfolio of metabolic disease drugs, wellness injections, and veterinary medicines.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition